all report title image
  • Published On : Aug 2022
  • Code : CMI5149
  • Industry : Pharmaceutical
  • Pages : 174
  • Formats :

Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. Age-related macular degeneration (AMD) is an eye disease that can blur central vision. It happens when aging causes damage to the macula, part of the retina (the light-sensitive tissue at the back of the eye). There are 2 types of age-related macular degeneration, such as dry and wet. Most people with AMD have dry AMD. This is when the macula gets thinner with age. Dry macular degeneration is a common eye disorder among people over 50. Wet AMD causes rapid and progressive central vision loss due to leaking blood vessels in the eyes. However, there is no cure, but treatment for macular degeneration (AMD) may slow the disease and keep people from having a severe loss of vision. Consult a doctor about the best way to manage the condition.

Market Statistics:

The global macular degeneration treatment market was valued at US$ 8,208.7 Mn in 2021 and is forecast to reach a value of US$ 13,195.7 Mn by 2028 at a CAGR of 7.0% between 2022 and 2028.

North America held dominant position in the global macular degeneration treatment market in 2020, accounting for 38.5% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Macular Degeneration Treatment Market Share (%), by Region, 2021

Macular Degeneration Treatment  | Coherent Market Insights

Recent Developments:

In February 2021, Roche announced detailed results from phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema and neovascular or wet age-related macular degeneration (nAMD).

In February 2020, Novartis received a European Commission approval for marketing of Beovu. It is an anti-VEGF agent used for treating wet-AMD patients.

CMI table icon

Macular Degeneration Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 8,208.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2020 to 2028 CAGR: 7.0% 2028 Value Projection: US$ 13,195.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Dry Age-related Macular Degeneration and Wet Age-related Macular Degeneration
  • By Stage Of Disease: Early-stage AMD, Intermediate AMD, and Late-stage AMD
  • By Route Of Administration: Intravenous Route and Intravitreal Route
  • By Sales Channel: Ambulatory Surgical Centres, Hospitals, and Other Sales Channels
Companies covered:

Bayer AG, REGENXBIO Inc., Aerie Pharmaceutical Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, and Bausch Health Companies Inc., among others

Growth Drivers:
  • Increasing burden of retinal disorders worldwide
  • Growing geriatric population across the globe
Restraints & Challenges:
  • Lack of awareness regarding macular degeneration
  • Increasing usage of off-label medications

Market Drivers:

  1. Increasing burden of retinal disorders worldwide is expected to propel growth of the global macular degeneration treatment market over the forecast period. For instance, retinal disorders have emerged as potential threats in both developed and developing countries. The prevalence retinal disorders is increasing, and as a result, vision loss is becoming a major public health concern. According to the BrightFocus Foundation (brightfocus.org), around 11 million people in the United States have some form of age-related macular degeneration, and this number is expected to reach around 22 million by 2050.
  2. Growing geriatric population across the globe is expected to boost the growth of the global macular degeneration treatment market during the forecast period. Retinal disorders increased with ageing. AMD is the most common cause of blindness prevalent in developed countries, particularly in people older than 60 years. According to the World Health Organization (WHO), in 2019, the number of people aged 60 years and older was 1 billion. This number is expected to reach around 1.4 billion by 2030 and 2.1 billion by 2050.

Figure 2. . Global Macular Degeneration Treatment Market Share (%) in Terms of Value, by Type, 2021

Macular Degeneration Treatment  | Coherent Market Insights

Market Restraints:

  1. Lack of awareness regarding macular degeneration is expected to hamper the growth of the global macular degeneration treatment market. AMD is a major cause of irreversible blindness, and awareness regarding AMD is important to prevent a blindness. However, lack of awareness among people about AMD is significantly low, especially in developing countries. Large-scale public campaigns and educational programs are essential to raise awareness regarding AMD.
  2. Increasing usage of off-label medications is expected to hinder growth of the global macular degeneration treatment market. Off-label drug use refers to the practice of prescribing a drug for a different purpose than what the FDA approved. In September 2019, MHRA (Medicines and Healthcare products Regulatory Agency) has clarified its position on the use of Roche's Avastin off-label as the treatment for wet AMD. In 2018, the High Court ruled that CCGs can prescribe Bevacizumab (Avastin) off-label for wet AMD.

Market Opportunities:

  1. Increasing demand for safe and effective treatment is expected to provide significant growth opportunities for players in the global macular degeneration treatment market. For instance, Age-related macular degeneration is prevalent and debilitating disease with the rise in demand for treatment. There is no cure, but treatment may slow the disease and keep people from vision loss. In May 2022, Chugai Pharmaceutical Co., Ltd. launched Vabysmo Intravitreal Injection 120 mg/mL for the treatment of AMD associated with subfoveal choroidal neovascularization and diabetic macular edema (DME).
  2. Rise in awareness among people about macular degeneration is expected to offer lucrative growth opportunities for players in the macular degeneration treatment market. For instance, AMD is a major cause of irreversible blindness, and awareness regarding AMD is important to prevent a blindness. Large-scale campaigns & programs are essential to raise awareness among people regarding AMD. The National Eye Health Education Program (NEHEP) is dedicated to raising awareness, especially in February, about vision and aging.

Market Trends/Key Takeaways:

  1. Frequent approvals and launches of novel products is expected to drive growth of the global macular degeneration treatment market. For instance, in October 2021, Roche announced that the Food and Drug Administration (FDA) has approved Susvimo (100 mg/mL ranibizumab injection) for the treatment of wet, or neovascular, age-related macular degeneration (AMD), a condition that can lead to rapid and severe loss of vision.
  2. Introduction of novel products by market players is expected to augment the growth of the global macular degeneration treatment market. For instance, in September 2019, Boehringer Ingelheim and Inflammasome Therapeutics Inc. signed an agreement to develop three therapies for patients suffering with retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).

Competitive Landscape:

  1. Hoffmann-La Roche Ltd
  2. Novartis AG
  3. Pfizer Inc.
  4. Panoptica
  5. Bausch Health Companies Inc.
  6. Regeneron Pharmaceutical Inc.
  7. Aerie Pharmaceutical Inc.
  8. REGENXBIO Inc.
  9. Bayer AG

Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula. There are 2 types of age-related macular degeneration, such as dry and wet. There is no cure, but macular degeneration (AMD) treatment help slow the disease and keep people from having a severe vision loss. However, the treatment depends on the stage and type. Dry AMD tends to progress more slowly than the wet type, and there is not, as of yet, an approved treatment or cure. The dry type is more common, but it usually progresses slowly (over years). However, treatment depends on the type of AMD.

Market Dynamics:

Increasing prevalence of retinal disease, growing geriatric population, rise in demand for safe and effective treatment, and increasing number of clinical trials are major factors expected to propel growth of the global macular degeneration treatment market. For instance, according to the Centers for Disease Control and Prevention (CDC), age-related macular degeneration is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older, and the number of older Americans is projected to nearly double from 48 million to 88 million in 2050.

In September 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye conditions, including neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.

Key features of the study:

  • This report provides in-depth analysis of the global macular degeneration treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global macular degeneration treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Bayer AG, REGENXBIO Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Aerie Pharmaceutical Inc., and Bausch Health Companies Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global macular degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global macular degeneration treatment market.

Detailed Segmentation:

  • Global Macular Degeneration Treatment Market, By Type:
    • Dry Age-related Macular Degeneration
    • Wet Age-related Macular Degeneration
  • Global Macular Degeneration Treatment Market, By Stage of Disease:
    • Early-stage AMD
    • Intermediate AMD
    • Late-stage AMD
  • Global Macular Degeneration Treatment Market, By Route of Administration:
    • Intravenous Route
    • Intravitreal Route
  • Global Macular Degeneration Treatment Market, By Sales Channel:
    • Ambulatory Surgical Centres
    • Hospitals
    • Other Sales Channels
  • Global Macular Degeneration Treatment Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • South America
    • Middle East & Africa

Frequently Asked Questions

The global macular degeneration treatment market size is estimated to be valued at US$ 8,780.6 Million in 2022 and is expected to exhibit a CAGR of 7.0% between 2022 and 2028.
Increasing burden of retinal disorders worldwide and growing geriatric population across the globe are fueling the growth of the market.
Wet Age-related Macular Degeneration segment is the leading type segment in the market.
Lack of awareness regarding macular degeneration and increasing usage of off-label drugs are the major factors restraining growth of the market.
Major players operating in the market are Bayer AG, REGENXBIO Inc., Aerie Pharmaceutical Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, and Bausch Health Companies Inc., among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo